diabetic macular edema diabetic retinopathy diabetic macular edema bevacizumab anti-
Conditions
Interventions
1. BCVA increase 1 or more than 1 line of snellen chart
2. or CST decrease 20% or more than 20% from baseline. ,1. BCVA decreas or not improved than 1 line of snellen chart
2. or CST increase or decr
Prevention,Prevention
good clinical response,poor clinical response
Sponsors
Khon Kean university
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. diabetic macular edema treated with intravitreal bevacizumab injection 2. older than 18 years old 3. initial visual acuity less than or equal to 6/12.
Exclusion criteria
Exclusion criteria: 1. Diabetic mellitus type I 2. previous vitrectomy or gas injection, previous treatment with focal laser or intravitreal anti-VEGF or intravitreal corticosteroid injection 3. presence of significant media opacity (e.g., mature cataract, vitreous hemorrhage or corneal scar), and co-existing with macular disease (e.g., age related macular degeneration, vascular occlusive disease.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| predictive factors on clinical response; age,sex,laterality,duration of DM,insulin used,FBS,HbA1C march 2019 to december 2019 correction all data from medical record and divided in 2 group by best corrected visual acuity and c | — |
Secondary
| Measure | Time frame |
|---|---|
| Best corrected visual acuity (BCVA) and central subfoveal thickness improvement after treatment march 2019 to december 2019 best corrected visual acuity by snellen chart and central subfoveal thickness from OCT at first vis | — |
Countries
Thailand
Contacts
Public Contactnatnaree engchuan
Faculty of medicaine, Khon Kean university
Outcome results
None listed